Full video transcriptClick to expand
Auto-generated transcript of @anais_dena's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00day, and we have a great experience, since we are already
- 0:09responsible for new activities, and we must always be able to be able to have new activities.
- 0:16And while the question of the day is not very important, it is important for the day because we have to use HD
- 0:20and the way we can do things for each day.
- 0:22When we have to do everything that we get, that we can do exactly what we need to do,
- 0:26But that's why I'm not going to any other of the game,
- 0:28and that's why you always want to take the best steps,
- 0:30and that's why I'm not going anywhere.
- 0:34And so when I was about to be able to have this game
- 0:38of course, I was going to leave the game of the game
- 0:41in the past and over again.
- 0:43So I go to find out how you can do it,
- 0:45that's why I'm not going anywhere else,
- 0:47and I go to the game of the game of the game of the game
- 0:50and I go to the game of the end.
- 0:51Because I was in the end of the game and then I go to the game
- 0:55Now we're going to have a process to help our views,
- 0:59and to make a new product in a different way,
- 1:01so that we can get to the next one.
- 1:04We will be able to make it to the end of the day.
- 1:07That is why we are here.
- 1:09All the details are not just about the new product.
- 1:13We want to offer you a better product.
- 1:16We want to offer you a better product,
- 1:19and let's come out with a better product.
- 1:22because we're expecting the result of the
- 1:24Himself, the same as ourselves, the same as like
- 1:28The some amongst others
- 1:29we are interested to
- 1:30let it be
- 1:31I'm not going to know exactly what I'm talking about
- 1:32but I want to make sure that my video is
- 1:34I'm not going to ask you this
- 1:36I'm not going to look as simple as possible
- 1:38but maybe I could not
- 1:41I don't have to do this
- 1:42I don't have to do it
- 1:44I aren't going to make it as simple as I can
- 1:46but I'm not going to make it as simple as you can
- 1:48and I'm not going to make it as simple as you can
- 1:50in terms of the most difficult job.
- 1:53So, I'm just going to talk about the idea that I'm busy,
- 1:57I'm in a business, I'm in a business, and I'm in a business,
- 2:00I'm going to think about this business,
- 2:03I'm not going to do anything like that,
- 2:05but I'm going to think about the idea that I've managed to do it.
- 2:08This is the way that I'll be able to stay in general,
- 2:10and I think that's the only way that I'm going to be able to stay in general,
- 2:14in terms of responsibility.
- 2:15You know what?
- 2:16And then we've already got these videos with our other videos.
- 2:19We're using these photos that we're going to hear from.
- 2:22Is it something we can't find?
- 2:24I will try to make a video about myimeter for a small body.
- 2:29It is not related to the controller.
- 2:32But I don't need space!
- 2:33The capability of this picture is clear.
- 2:36Because of the other videos,
- 2:39I think it's a good song for me to go to the very beginning.
- 2:41But if you want to meet people who areousandknife, you should be dependent on the success of the
- 2:47success who are gained in the community and not only for everyone who's working in the community,
- 2:51you could be interested in other possibilities, and you should be able to provide for the communities in the community.
- 2:55And until then, it is very good to help you with the mobility and the processes for one,
- 2:58or the two, or two-part yourself ?
- 3:01I will, for the first time, I will put some lead happening here before you come.
- 3:07And because of everything we did in this zone,
- 3:09we had to move on this one.
- 3:10Thank you so much for your service and thank you very much for listening.
- 3:36When you give a video, you can be asked about the process of doing this, because of the process of doing this.
- 3:44They have a lot of ideas for us because of the symmetric products and the cost of the cultural activities.
- 3:51They have a lot of resources for us, for this case.
- 3:56The information you will get made from the information,
- 4:00I hope you enjoyed the video and if you enjoyed this video, please give me a thumbs up and like and subscribe to my channel.
Liraglutide (Victoza) for weight loss: what the evidence says
Quick answer
This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.8 mg daily. The higher-dose formulation, Saxenda (3.0 mg), holds the FDA approval for chronic weight management, and conflating these two indications in patient-facing content can create unrealistic expectations or inappropriate off-label use. Because the audio transcript is largely unintelligible, likely due to Spanish-to-English auto-caption failure, no specific medical claims can be directly verified from this video's spoken content.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Liraglutide (Victoza) for weight loss: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Liraglutide (Victoza) for weight loss: what the evidence says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Liraglutide (Victoza) for weight loss: what the evidence says" from Anaís Dena. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.
The reason this review is not generic is the source wording and the canonical claim label "glp1 mi proceso con victoza weightloss liraglutida weightlosstran." In this clip, the useful excerpt is: "day, and we have a great experience, since we are already responsible for new activities, and we must always be able to be able to have new activities." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.8 mg daily. The higher-dose formulation, Saxenda (3.0 mg), holds the FDA approval for chronic weight management, and conflating these two indications in patient-facing content can create unrealistic expectations or inappropriate off-label use. Because the audio transcript is largely unintelligible, likely due to Spanish-to-English auto-caption failure, no specific medical claims can be directly verified from this video's spoken content.
- Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the weight management approval. They are not the same product for regulatory or clinical purposes.
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found 3.0 mg liraglutide produced 8.4 kg average weight loss over 56 weeks vs. 2.8 kg on placebo in non-diabetic adults.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the weight management approval. They are not the same product for regulatory or clinical purposes.
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found 3.0 mg liraglutide produced 8.4 kg average weight loss over 56 weeks vs. 2.8 kg on placebo in non-diabetic adults.
- Weight regain is common after stopping liraglutide. Davies et al. (2015, Lancet Diabetes and Endocrinology) found most patients regain weight within months of discontinuation.
- Liraglutide carries an FDA boxed warning for potential thyroid C-cell tumor risk observed in rodents, and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
- Approximately 40% of participants in the SCALE trial reported nausea, making it the most common side effect, typically peaking during dose escalation phases.
- The video transcript is largely incoherent, most likely due to auto-captioning failure on Spanish-language audio, meaning no specific spoken medical claims can be verified or fact-checked directly.
- Compounded liraglutide products are not FDA-approved and cannot be assumed equivalent to brand-name Victoza or Saxenda in potency, sterility standards, or clinical validation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @anais_dena actually say?
Honestly? It is hard to tell. The transcript for this video is largely incoherent, likely the result of auto-generated captions failing to accurately capture Spanish-language audio. What we can piece together from context, the hashtags, and visual cues is that this creator documented a personal weight loss experience using liraglutide (brand name Victoza), a GLP-1 receptor agonist. The caption uses hashtags like #victozaweightloss, #liraglutida, and #perdidadepeso (weight loss in Spanish), and frames this as a personal transformation journey. There is no clear verbal claim about dosage, mechanism, or medical outcomes that we can directly quote and verify. What we have is a before-and-after story shared with nearly 94,000 viewers, many of whom may be considering GLP-1 medications themselves.
Does the science back this up?
The general premise, that liraglutide can support meaningful weight loss, is well-supported by clinical evidence. Whether Victoza specifically is the right tool for weight loss is a more complicated conversation.
Liraglutide is FDA-approved for two distinct purposes. Victoza (1.2 mg or 1.8 mg daily) is approved for type 2 diabetes management. Saxenda (up to 3.0 mg daily) is the higher-dose version approved specifically for chronic weight management. The SCALE Obesity trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that adults without diabetes taking 3.0 mg liraglutide lost an average of 8.4 kg over 56 weeks, compared to 2.8 kg on placebo. That is a real effect, but it is dose-dependent. Using Victoza off-label for weight loss, at diabetes doses, may produce less pronounced results than Saxenda.
GLP-1 receptor agonists work by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin sensitivity. These are legitimate, studied mechanisms, not wellness industry hand-waving.
What did they get wrong (or right)?
Because the transcript is essentially unusable for factual extraction, we cannot attribute specific errors to the creator's spoken words. That is not a pass, though. It is a problem.
What this video does implicitly, through its hashtag framing, is position Victoza as a weight loss drug. That is only partly accurate. Victoza is a diabetes drug that can produce weight loss as a secondary benefit. Saxenda is the weight loss drug. Conflating the two in a 94,000-view video, without that distinction, could lead viewers to seek a diabetes medication when a weight-management-specific approval exists, or to expect Saxenda-level results from a Victoza dose.
On the positive side, personal documentation of GLP-1 experiences, when done responsibly, helps reduce stigma around medical weight management. There is real value in patients sharing that these medications involve an ongoing process, not a one-time fix. The creator's framing of this as a journey rather than an overnight transformation is, at minimum, not misleading in tone.
What should you actually know?
If you are watching this video and wondering whether liraglutide is right for you, here is what the evidence actually says.
- Liraglutide requires a prescription and medical supervision. It is not a supplement or a shortcut.
- Victoza and Saxenda contain the same active ingredient at different approved doses for different indications. They are not interchangeable without a prescriber's guidance.
- Common side effects include nausea, vomiting, and diarrhea, particularly during dose escalation. The SCALE trial reported that roughly 40% of participants experienced nausea.
- Weight loss with liraglutide typically requires sustained use. Davies et al. (2015, Lancet Diabetes and Endocrinology) found that stopping the medication results in weight regain in most patients.
- Liraglutide carries an FDA boxed warning about a potential risk of thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
Seeing a transformation video on TikTok is not a substitute for a clinical evaluation. If you are curious about GLP-1 therapy, that conversation belongs with a licensed provider who knows your full medical history.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Anaís Dena · TikTok creator
93.7K views on this video
Mi proceso con #victoza #weightloss #liraglutida #weightlosstransformation #victozaweightloss #inyeccion #perdidadepeso #diabetes #obesidad #fy #amorpropio #loveyourself #fyp #foryoupage #paratii
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about victoza (liraglutide 1.8 mg)?
Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the weight management approval. They are not the same product for regulatory or clinical purposes.
What does the video say about the scale obesity trial (pi-sunyer et al., 2015, nejm) found?
The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found 3.0 mg liraglutide produced 8.4 kg average weight loss over 56 weeks vs. 2.8 kg on placebo in non-diabetic adults.
What does the video say about weight regain?
Weight regain is common after stopping liraglutide. Davies et al. (2015, Lancet Diabetes and Endocrinology) found most patients regain weight within months of discontinuation.
What does the video say about liraglutide carries an fda boxed warning for potential thyroid c-cell?
Liraglutide carries an FDA boxed warning for potential thyroid C-cell tumor risk observed in rodents, and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
What does the video say about approximately 40% of participants in the scale trial reported nausea,?
Approximately 40% of participants in the SCALE trial reported nausea, making it the most common side effect, typically peaking during dose escalation phases.
What does the video say about the video transcript?
The video transcript is largely incoherent, most likely due to auto-captioning failure on Spanish-language audio, meaning no specific spoken medical claims can be verified or fact-checked directly.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Anaís Dena, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.